** Shares of Paradigm Biopharmaceuticals PAR.AX fall as much as 25.9% to A$0.430, their lowest levels since Nov 26
** The drug development firm announces A$16 mln ($10.23 mln) placement to institutional and sophisticated investors
** Issue price of A$0.40 represents a discount of 31% to last close on Dec 4 when trading was halted pending capital raising announcement
** Funds to support global Phase III trials for osteoarthritis treatment with iPPS, beginning in Australia and expanding to key U.S. sites
** Objective of Phase III trials include demonstration of improvement in pain and function with subcutaneous injections of pentosan polysulfate sodium (iPPS)
** Stock has risen 27.1%, YTD
($1 = 1.5642 Australian dollars)
(Reporting by Namrata Verma in Bengaluru)
((namrata.verma@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.